Skip to main content

Table 4 Comparison of mean logs ratios of the different macrolide–resistant genes before, during and after treatment

From: Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin

   Placebo Azithromycin  
   Mean* SD Mean SD P value**
mefA M6 −0.22 (n = 27) 1.00 0.51 (n = 34) 0.47 0.0001
M12 −0.39 (n = 26) 1.21 0.33 (n = 30) 0.68 0.002
ermF M6 −0.14 (n = 11) 1.35 0.86 (n = 18) 0.99 0.0687
  M12 0.15 (n = 12) 0.94 1.04 (n = 17) 0.80 0.0124
ermB M6 −0.32 (n = 20) 1.48 0.69 (n = 33) 0.93 0.0116
  M12 −0.42 (n = 18) 1.33 0.89 (n = 30) 1.05 0.0013
  1. *mean of the log gene abundance ratio compared to baseline
  2. **p values for comparison of mean abundance at either 6 or 12 months and baseline, by Wilcoxon ranked sum test